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Pompe’s Disease and the Effects ofAlpha-Glucosidase Deficiency 
Aaron Richler 
Overview: 
The energy that the body needs in order to function is obtained from carbohydrates that 
we get through our diet. These carbohydrates are monosacharides, disaccharides and 
polysacharides. The polysaccharides and disaccharides are hydrolyzed to monosaccharide’s such 
glucose (which comprises roughly 80%) fructose and galactose. Most cells convert the fructose 
and galactose to glucose. The body can use the glucose or store it. If energy is needed, glucose 
can be oxidized through the many reactions of glycolysis which gives a net production of 2 ATP 
and 2 NADH from one molecule of glucose. In the presence of oxygen the product of glycolysis 
pyruvic acid will be decarboxilated to Acetyl Coenzyme A (Acetyl COA) in the mitochondrial 
matrix forming carbon dioxide and 2 NADH in the process. The acetyl COA subsequently enters 
the citric acid cycle (the Krebs cycle) where after a series of reactions, 2 molecules of ATP, 4 
molecules of carbon dioxide, 6 NADH and 2 FADH2 are produced. The NADH’s enter the 
electron transport chain and over a series of reactions with the proteins in the mitochondrial 
matrix form 3 ATP per molecule of NADH and 2 ATP per molecule of FADH2. (Murray)   
In accordance with homeostasis, the presence of high energy will cause the body to 
balance energy levels by forming storage molecules of energy for use in times of need. This 
storage form of glucose is called glycogen; the synthesis is called glycogenesis. This glycogen 
can later be degraded into is monomer units for the use in oxidative phosphorylation. (Champe) 
 
Glycogen is a branched chain 
of alpha-D-glucose. Most of the 
glucose molecules are attached to each 
other via a carbon to oxygen to carbon 
bond known as a glycosidic bond. In 
the linear portions of glycogen the 
glycosidic bond is known as the 1,4 
linkage this is a bond between the 
carbon labeled 1 and the carbon 
labeled 4 on the next glucose. Every 8-
10 glucose molecules there is a 1, 6 
glycosidic bond causing the above 
mentioned characteristic branching of 
glycogen. (Murray) [Figure 1] 
Glycogen is mainly stored in the skeletal muscle and the liver while it has been found in 
almost every cell in the body in trace amounts. The liver cell has the most glycogen consisting of 
up to 6% of its total weight. Alternatively in muscle cells glycogen is never more than 1% its 
total mass. However, because the total mass of muscle in the body is larger than that of the liver, 
overall, muscle contains more glycogen than the liver. (Murray)  
Muscle contains glycogen for its own use. When in need of energy it will break down the 




its reserves of glycogen after exercise for example and will not be affected during short periods 
of fasting. Yet, the liver stores glycogen in order to maintain blood glucose between meals; 
higher levels of glycogen are found after meals and lower levels during fasting. (Murray)  
There are five enzymes that catalyze the reactions of glycogenesis. The first enzyme 
glucokinase which is found in liver cells and beta cells of the pancreas phosphorylates glucose. 
Additionally, hexokinase, a similar enzyme phosphorylates glucose in most of the other cells of 
the body. This phosphorylation creates Glucose 6-PO4 which is the substrate for the enzyme 
phosphoglucomutase which transfers the phosphate group to the 1st carbon. Next, uridine 
triphosphate (UTP) a high energy molecule reacts with glucose 1 PO4 and the enzyme UDP-
pyrophosporylase forming UDP-glucose. Being that glucose cannot be added to other single 
molecules of glucose UDP glucose attaches to glycogenin a molecule with a tyrosine side chain 
to form the primer for additional glucoses to be attached. After adding two molecules of glucose 
to this base stand, the enzyme glycogen synthase continuously acts with UDP-glucose to form a 
long linear chain of glucose attached via alpha-1,4-glycosidic bonds. The ends of the chain to 
which this enzyme attaches to are 
called nonreducing ends. Branches 
are formed in the chain in order to 
increase solubility and to increase 
nonreducing ends. By increasing non 
reducing ends enzymes can easily 
remove and attach glucose molecules 
thereby increasing the rate of 
synthesis as well as degradation of 
the chain. (Champe) 
The branches are formed by 
the enzyme glucosyl 4:6 transferase. 
The enzyme breaks a 1,4 bond in the 
linear portion of the chain usually 
forming 5-8 glycosyl chains and 
attaches this small chain to another 
spot on the chain via a 1,6 linkage. 
This results in two more nonreducing 
ends. 
The new reducing ends can 
then be elongated by glycogen 
synthase and glucosyl 4:6 transferase 
usually removing 5-8 terminal 
molecules and adding them to 
another point in the chain by 1, 6 
linkage and so on forming branched 
glycogen.(Champe) The remaining 
branched chain of glycogen after the 
action of glycogen phosphorylase is 
called the limit dextrin. Next, the 







removes 3 of the four remaining glucose units before the branch point and adds them to the 
remaining linear chain via a 1,4 linkage. Then the enzyme amylo-alpha-(1,6)-glucosidase cleaves 
the one remaining glucose molecule attached via 1,6 linkage before the branch point to which the 
cycle starts again with the glycogen phosphorylase removing linear portions of the chain and so 
on until the glycogen molecule is completely degraded. (Champe) 
In response to low blood glucose glycogenolysis is initiated. First the enzyme glycogen 
phosphorylase cleaves the alpha-1,4 glycosidic bonds of the linear portions of the chain of 
glycogen. This enzyme stops when there are four glucose units left before a branching point. The 
enzyme Alpha-1, 4-glucosidase (lysosomal enzyme) is another enzyme that cleaves the alpha-1, 
4-glycosyidc bonds until there are four glucose units left in that chain before the branch point. 
(Champe) 
The remaining branched chain of glycogen after the action of glycogen phosphorylase is 
called the limit dextrin. Next, the enzyme glucosyl (4:4) transferase removes 3 of the four 
remaining glucose units before the branch point and adds them to the remaining linear chain via 
a 1,4 linkage. Then the enzyme amylo-alpha-(1,6)-glucosidase cleaves the one remaining glucose 
molecule attached via 1,6 linkage before the branch point to which the cycle starts again with the 
glycogen phosphorylase removing linear portions of the chain and so on until the glycogen 
molecule is completely degraded. (Champe) [Figure 2] 
The products of glycogenolysis are Glucose-1-phosphate and glucose. Glucose-1-
phosphate is converted to glucose -6-phosphate by phosphoglucomutase. In the liver Glucose-6 
po4 is converted to glucose by glucose-6-phophotase and then released into the blood. In skeletal 
muscle Glucose-6-po4 is converted to glucose which is used for energy in the form of ATP from 
glycolysis.(Murray) 
Regulation of Glycogen synthesis and degradation in the body occurs through allosteric 
regulation. This is charachterized by the inhibition of enzyme pathways by changing the shape of 
a molecule so that it cannot work or activation of a protein to make it work.  
Glycogenesis will be initiated when an increased concentration of glucose 6-PO4 is in the 
cytosol of the cell. The enzyme Glycogen synthase is allosterically activated via positive 
feedback. This causes the enzyme to synthesize glycogen via pathway mentioned above. 
With increased concentration of glucose, glucose 6-PO4, and ATP the enzyme glycogen 




In order to break down glycogen in a particular cell the glycogen synthesis pathway must 
be inhibited. This inhibition is carried out by cAMP pathway/ Adenylate cyclase pathway.  
In response to hormone such as glucagon attaching to it the membrane receptor couples 
with the G-protein in the membrane and activates adenylate cyclase enzyme in the membrane. 
When activated the enzyme catalyzes the reaction of ATP to form 3,5, Adenosine 
monophosphate (cAMP). CAMP then activates a protein kinase which then phosphorylates a 
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particular protein substrate in the particular pathway that is occurring. This phosphorylated 
protein can then act on other substrates. (Champe) 
Another process that uses the cAMP pathway is the inhibition of glycogen synthesis. In 
response to glucagon, epinephrine, or low levels of energy glycogen synthesis will to be stopped. 
Glucagon or epinephrine activates adenylate cyclase and eventually the cAMP activates a kinase 
that inactivates glycogen synthase by phosphorylating it. This inactivated enzyme is now 
referred to as Glycogen synthase b. In the phosphorylated form the glycogen synthase b cannot 
synthesize more glycogen. (Champe) 
Activation of Glycogen degradation is also carried out by cAMP pathway by the binding 
of glucagon or epinephrine. Activated cAMP dependent kinase phosphorylates and activates 
phosphorylase kinase. Phosphorylase kinase then phosphorylates the enzyme glycogen 
phosphorylase b to glycogen phosphorylase a which starts hydrolyzing glycogen. (Champe) 
 
GSD 
The first known diagnosis of GSD occurred in 1928 by the physicians Snappes and Van 
Crefald. The case involved was a 7 year old presenting with hepatomegaly or liver tumor and the 
patient had a very low fasting glucose yet very high acetone and beta-hydroxybuterate in the 
urine. After various tests the term “insufficient mobilization of glycogen” was used and the 
disease was defined as a debranching enzyme deficiency. Later, this disease was termed GSD III 
or Cori’s disease. Over the next few years more cases of GSD were found by various physicians 
and chemists that found increased amounts of glycogen in patients’ organs. (Fernandes) 
There are more than 14 known glycogen storage diseases. All of these diseases are 
genetic and characterized by an abnormal type or quantity of glycogen in tissues, usually caused 
by a missing or defunct enzyme in the pathway. Nearly all of the proteins involved in 
glycogenolysis and glycogenesis have been the cause of a particular GSD. The defunct or 
missing enzyme can affect the liver function or muscle function or both. The diseases are 
diagnosed acc. to types of symptoms that are evident in the patient. (Chen).  
Glycogen storage diseases have three general groups hepatic, myopathic and 
miscellaneous. Clinically, the diseases are numbered but only the first through seventh are 
traditionally used; the others are described according to enzyme affected (Harrsisons).  
Hepatic types are diseases that are grouped acc. to their hepatic hypoglycemic 
pathophysiology in that those diseases that affect the liver affect sugar levels too because the 
liver is mainly responsible for carbohydrate metabolism (Chen). These are Von Gierke’s disease 
(Type I) a glucose-6-phosphotase deficiency affects liver, kidney and intestine because of 
increased glycogen storage which causes severe hypoglycemia, fatty liver and 
hyperlacticacidemia, Cori’s Disease (Type III) which is a debranching enzyme deficiency 
causing accumulation of branched polysaccharide with symptoms such as hepatomegaly, 
hypoglycemia and hypotonia and Hers’ disease (Type VI) which also has high liver glycogen 
content and hypoglycemia. Others include Andersen’s disease (Type IV) which is caused by a 
lack of branching enzyme as well as Type IX which is caused by a phosphorylase kinase 
deficiency. These diseases have characteristic symptoms of expected liver and sugar diseases 
such as hypoglycemia, hepatomegaly (Chen)  
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The myopathic type is a group of muscle-energy pathophysiology related diseases. These 
diseases are McArdle’s disease (Type V) a skeletal` muscle glycogen phosphorylase deficiency 
with symptoms such as myglobinuria, muscle pain, muscle cramps and muscle enzymes in serum 
after exercise., Tarui’s disease (Type VII) which is to type V but also can have symptom of 
hemolytic anemia. The miscellaneous group includes of Anderson’s (Type IV) a branching 
enzyme deficiency and Pompe’s (Type XI). These are different in that their symptoms and 
causes are not specifically related to any group (Chen). There are other GSD’s that are 
characterized by deficiencies of cAMP dependent protein kinase or adenlyl cyclase. 
The overall frequency of glycogen storage disease in populations of European decent is 
around 1 in 23,000 births with types I,II,III,VI, and IX the most common comprising of 
approximately 90% of all cases. Inheritance patterns of disease are generally autosomal 
recessive. However, there are forms that have been found to show x-linked patterns. (Chen) 
 
GSD Type 2 – Pompe’s  
 
Glycogen storage disease type ll was discovered by Pompe in 1932 when a 7 year old girl 
was found with massive accumulation of glycogen in her tissues. The discovery made Pompe the 
third physician to discover a GSD. In that same year and in the years to come many more cases 
of cardiomegaly, hypotonia and death before the age of 1 were found with physicians reporting 
additional symptoms associated. (Hirschorn) 
The disease is known as Glycogen storage disease type 2, Pompe’s Disease, acid maltase 
deficiency, acid α-glucosidase deficiency or lysosomal enzyme deficiency.  Initially the disease 
was only referred to as idio cardiomegaly but in 1963 with new biochemical discoveries in cell 
biology and metabolic pathways it was termed as a glycogen storage disease (Chen). 
Additionally, it was termed a lysosomal storage disease when Hers eventually defined a 
lysosomal storage disease as having 1) lysosomal enzyme deficiency 2) deposit build up present 
in vacuoles (Chen). The discovery by Pompe also led to the startup of research into lysosomal 
storage diseases with over 40 known today.  
The lysosome was first discovered by Christian de Duve in 1955 as a membrane bound 
vacuole in human cells containing hydrolytic enzymes all active at acid pH (de Duve). These 
enzymes he postulated were able to break down macromolecules one of which is glycogen. 
(Campell) 
Pompe’s disease is caused by a genetic deficiency of the enzyme alpha-1,4-glucosidase 
(lysosomal enzyme) which is found in the lysosome and primary and secondary vacuoles of 
cells. Normally this enzyme as well as glycogen phosphorylase cleaves the alpha 1,4 glycosidic 
bonds of the branched chains of glycogen until there are 4 glucose molecules left before the 
branching point where the enzyme glycosyl 4,4 transferase cleaves the glucose molecules until 
the branch point. But a deficiency in the lysosomal enzyme will cause a build up in the glycogen 
branches because of the inability of glycosyl 4,4 transferase to function on the glycogen. This 
leads to a build up of partially branched glycogen in the cell cytoplasm as well as glycogen 








A postulated mechanism of action that causes the symptoms of the disease is that the 
deficiency of alpha-glucosidase causes a build up in the lysosomes of the cell. After reaching a 
capacity as well as with mechanical action of muscle the lysosomes rupture spilling their 
contents into the cytosol. (Griffin) An increase in protein breakdown has been seen in various 
studies by both radioactive isotope and stable tracers. This breakdown occurs because of the 
cells’ low levels of energy which initiates a cellular response by harvesting energy from the 
muscle protein and thus the wasting away of muscle and the subsequent symptoms such as 
muscle pain and hypotonia as well as respiratory problems are seen. (Bodamer) 
The clinical representation of Pompe’s shows a broad range of phenotypes all of them 
include myopathy but differ in other symptoms. There are three general groups of GDS 2 
infantile onset, juvenile onset and adult onset. The groups differ in their progression 
characteristics but all are 
characteristically confirmed 
by the absence or lack of the 
alpha-glucosidase.  Yet, 
studies have shown that 
severities of disease are in 
correlation with the lack of 
alpha-glucosidase, with 
infants and children usually 
having the worst forms. 
Additionally, symptoms 
seem to develop when there 
is less than 30% enzyme activity and increase in 




Infantile onset, otherwise known as the classic 
Pompe disease is the most common and the most severe of 
the three types of GDS2, causing cardio-respiratory death 
before the age of two years old. Most frequently it is 
reported in infants in the first months of life. Symptoms are 
generally severe cardiomegaly and hypotonia as well as 
macroglossia and rapid progressive weakness. Upon EKG 
testing as well as during autopsy it was found that both of 
the ventricles of the heart have increased thickness caused 
by the excess glycogen. (Chen) [Figure 4]  
 
Childhood-Juvenile Onset: 
The childhood juvenile onset group is characterized 
by symptoms occurring after the age of two years old (Chen). 
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The symptoms usually present are skeletal muscle involved without any major cardiomegaly. 
The disease progresses more slowly than that of the first type and patients usually die of 
respiratory failure before thirty years of age. (Chen)  
 
Adult Onset: 
Adult onset GSD2 presents as a slowly progressive disease. The disease is usually found 
in patients in their mid 20’s to 60’s. In all cases known so far the disease does not cause 
cardiomegaly but affects other skeletal muscles as well as the diaphragm. Weakness is usually 
first followed by lower back pain and loss of deep tendon reflexes. Other symptoms include 
somnolence, orthopnea, exertional dyspnea, and morning headache. (Chen) Death usually occurs 
from respiratory failure but being that the disease affects the respiratory muscles death may be 
caused by pulmonary hypertension and cardiac failure. 
Documented cases of patients that were athletically active, shows that patients can have 
completely normal lives before the onset of this disease.  
 
GSD 2b: Danon’s disease   
First discovered in 1981 in two boys by Morris J. Dannon, this subtype is characterized 
by patients with GSD2 symptoms such as cardiomyopathy with vacuolar storage of glycogen yet, 
interestingly, normal alpha-glucosidase activity. Other clinical symptoms are arrhythmias, 
mental retardation and a Creatine kinase rise to tenfold in some cases. Yet, the hallmark finding 
is that the vacuoles contained autophagy material with glycogen in skeletal and cardiac muscle. 
The disease has been shown to be caused by a deficiency of a major lysosomal membrane 
glycoprotein called lysosomal-associated membrane protein 2 (LAMP-2) with studies mapping 




The gene that codes for the enzyme alpha-glucosidase is located on chromosome 17 
(q21-23) and is designated GAA on the human gene map and has 20 exons, 19 introns and is 
approximately 20 kb long. There are over 180 mutations that exist with that number increasing. 
The mutations that are occurring are missense, nonsense, splice site mutations, and small 
deletions and insertions. However, around half of all the mutations found are due to missense 
mutations. (Hirschorn) 
In 1990 the gene was first cloned and cDNA strands were isolated. It was found that the 
enzyme created from the cDNA showed the same characteristics as the endogenous enzyme. 
(Hoefsloot) 
Interestingly, carriers of the disease show codominance in that they will have 50% 
functioning enzyme. Therefore they will not have symptoms of the disease as mentioned above 
that patients with more than 30% functioning enzyme are not affected. (van der Pleug) 
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The three clinical manifestations of the disease prompted investigators to conclude that 
the various phenotypes of the disease are caused by different locations of the various mutations. 
For instance, in 75% of the patients that had the slow progressive type of Pompe’s (which would 
include child and adult onset) were found to have the particular chromosomal mutation c.-32-
13T>G. Yet the other more severe forms were found to have other mutations such as c.1935C>A 
and c.2560C>T which are found in patients with no enzyme activity at all. (van der Pleug) 
Additionally, researchers found that the symptoms of the other 25% of the patients with the c.-
32-13T>G mutation showed varying amounts of functional enzyme leading to the possible 
theory that there are modulating factors involved such as diet and exercise. (van der Pleug) 
 
Testing:  
Being that in all cases of Pompe’s disease there is a deficiency of enzyme prenatal 
diagnosis is possible in groups that are at risk. Testing of the chorionic villi cells either cultured 
or uncultured during pregnancy with the artificial substrate 4-methlyumbelliferyl-alpha-D- 
glucopyranoside (4MUG) will give a probable diagnosis for infantile onset GSD2. This testing is 
advantageous because it allows for the diagnosis with only 12 weeks into pregnancy and one day 
to actually diagnose. (Chen) Additionally, a study in Thailand successfully tested an infant with 
electron microscopy of chorionic villi. Also, amniocenteses as well cordocenteses is possible. 
(Phupong) 
The artificial substrate 4MUG is also used in testing cultured skin fibroblasts. Skin 
fibroblasts contain large amounts of enzyme so if there is a deficiency it will be noted in 
accordance with strict standards. This test is advantageous in order to be able to use the same 
specimen over long periods of time. (van der Plaug) 
This same artificial substrate can be used in muscle biopsies. Muscle biopsies can 
differentiate between the infantile onset and adult onset. 
Additional testing includes the periodic acid Schiff (PAS) which tests for glycogen. The 
mechanism occurs through the reaction of periodic acid and glycogen which gives aldehyde 
products which then react with the Schiff reagent which gives off a purple color. (Kiernan) 
 
Treatments: 
The first study on the treatment of Pompe’s was done in a Japanese lab. They 
subsequently showed that they can restore some activity of the acid alpha glucosidase in a mouse 
model (Kikuchi). Five years later in 2003 the company Genzyme created cloned enzyme 
recombinant human acid alpha glucosidase (rhGAA) from transgenic rabbit milk or CHO cells 
and have shown great results. When either of these was given in high doses of 10mg/kg there 
was a significant diminishing of glycogen in the cells of skeletal and smooth muscle as well as 
heart and other organs. These results made it possible to apply for FDA testing. (Koeberl) 
Studies show that there is a critical threshold of about 30% of the average enzyme 
activity needed to prevent the symptoms of the disease. Enzyme therapy and replacement are in 
order to bring the patient up to the threshold but it seems that diet and exercise might lower this 
threshold. (van der Ploeg) 
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In 1983 Slonim and coworkers used a high protein diet to cure and raise the muscle 
function of a child with GSD 2. (Bodamer) This diet relied on the fact that the cell was utilizing 
energy from the breakdown of protein which is discussed above. Since then however, there is 
dispute whether such a diet would work, with recent reports showing that only 25% of patients 
show slight improvement of muscle function. Yet, even if this diet would work it is hard to get 
patients to eat a 30% protein diet. Furthurmore even if the patients can handle such a diet the 
patients gain considerable amount of wait which decreases their respiratory function thus 
removing any positive reasons for the diet.  
A recent study was done on the efficacy of rhGAA type called Myzozyme® in the 
treatment of infantile onset. The study showed that the younger the patients were when the 
therapy started the better their conditions would be. Infants younger than 6 months showed the 
best results with all of the patients surviving past 18 months and 83% ventilator free. On the 
other hand the group of infants that was 6-36 months old when the treatment started did not fair 
as well. But both groups did show thinning of the cardiac ventricular index, changes in growth 
and motor development. This study also established that doses 20 mg/kg cause less adverse 
events than 40 mg/kg of the enzyme. (Koeberl)  
There are problems with the treatment of the enzyme just like other synthetic protein 
therapies. The main problem that impeded the approval of Myzozyme® was the fact that when 
patients with no GAA activity were treat4ed with Myzozyme® they developed anti-rhGAA 
antibodies with fatal consequences.  
Yet a recent study showed the possibility of elimination of the antibodies with strict 
immune-modulation therapy and had successful results. Although there are various other 
reactions to this drug this therapy greatly increases the chance of survival of many of the patients 
even at later stages. (Mendelsohn) This drug is now being prescribed to Pompe’s disease patients 
of all ages with approval from the European commission and is in the final stages of FDA 
approval. 
There has been promising research regarding the neural deficits in Pompe’s patients that 
was documented just weeks ago. Researchers found that in comparison to a control group mice 
without the GAA gene have significant glycogen accumulation in the cervical spinal cord and 
other parts of the CNS. The study also included phrenic nerve monitoring which showed that 
mice without the GAA gene had deficient neural output. (DeRuisseau) This led to the conclusion 
that medications should be made to affect the nervous system as well as the musculatory system.  
 
Conclusion 
GSD 2 is an inherited autosomal recessive disorder that causes various mutations on the 
gene that codes for the enzyme acid-alpha glucosidase. The mutation will cause a decrease or 
stop in enzyme activity leading to a buildup of glycogen in the lysosomes of the cells. Due to the 
accumulation of the glycogen, severe complications such as cardiomegaly, hepatomegaly, 
hypotonia and others are seen. However, there is much hope for patients with this disease with 
the recent approval of the medication Myzozyme® as well as the continuing research into other 
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